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Abstract
The prevalence of the newly discovered pneumococcal serotype 6C has increased in some countries since the introduction of
seven-valent conjugate pneumococcal vaccine (PCV7). The distribution of invasive serogroup 6 serotypes, in Australia, including 6C
and 6D, has not been reported previously. During the period 1999 to 2008, 6097 isolates were referred to the New South Wales
Pneumococcal Reference Laboratory for serotyping. Of these, 847 were identiﬁed by Quellung reaction as belonging to serogroup 6
and 702 were available for further study. Serotypes were determined by serotype-speciﬁc PCR as follows: 6A, 197 (28.1%); 6B, 452
(64.4%); 6C, 52 (7.4%) and one 6D. The average numbers of invasive serogroup 6 isolates, per annum, fell from 62.2 before (2000–
2005) to 49.7 after (2006–2008) the introduction of PCV7. The proportions of invasive 6B fell (from 72.4% to 47.3%, p 0.03), those
of 6C rose (from 3.3% to 17%, p 0.02) signiﬁcantly and those of 6A remained fairly constant (24.3% vs 27%, p 0.69) between the
two periods. All 6C and 6D and selected 6A and 6B isolates were further characterized by multilocus sequence typing and sequence
analysis of cps genes cpsA-cpsB (wzg-wzh) and wchA-wciNbeta-wciO, wciP. Results showed considerable diversity within serotype 6C,
apparently as a result of both mutation and recombination. Sequence typing indicates that, in Australia, 6C has been largely derived
from 6A. The genetic diversity and rapid increase in incidence of serotype 6C causing invasive pneumococcal disease has potential
implications for vaccine efﬁcacy.
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Introduction
The capsular polysaccharide of Streptococcus pneumoniae is its
most important virulence factor [1] and serotyping has been
used as the primary criterion for classiﬁcation of pneumo-
cocci for decades [2]. A new serotype, 6C, was described in
2007 based on differences in reactions to monoclonal anti-
bodies between two groups of isolates that had been identi-
ﬁed by Quellung reaction as serotype 6A [3,4]. Several
recent studies have shown that the proportion of serotype
6C isolates has increased while those of serotype 6B—and
to a lesser extent 6A—have decreased since the introduc-
tion of the seven-valent pneumococcal conjugate vaccine
(PCV7) [5–7]. The existence of a new serotype, 6D (identi-
ﬁed as 6B by Quellung reaction, but carrying the variant wciN
found in serotype 6C) was predicted [8], shown experimen-
tally to be feasible [9] and, subsequently, putatively identiﬁed
by us among isolates carried in the nasopharynx by Fijian
children enrolled in an immunization study [10]. Bratcher
et al. [11] later demonstrated the unique capsular and anti-
genic structure of two naturally occurring serotype 6D iso-
lates from Korea.
The aim of this study was to determine the distribution
and characteristics of S. pneumoniae serotypes 6C and 6D
among isolates referred to the New South Wales (NSW)
Pneumococcal Reference Laboratory between 1999 and
2008 and changes following the introduction of routine infant
immunization with PCV7 in Australia, in 2005.
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Materials and Methods
Streptococcus pneumoniae isolates
All isolates from patients with invasive pneumococcal disease
in NSW and the Australian Capital Territory (combined pop-
ulation  7.4 million) have been referred, routinely, for sero-
typing to the NSW Pneumococcal Reference Laboratory,
Centre for Infectious Disease and Microbiology (CIDM),
Westmead Hospital, since 1999 (although referral was
incomplete early in this period). Non-sterile site isolates are
referred sporadically. A total of 6097 invasive isolates were
referred in the period 1999 to 2008. Of these, 679 (11.1%)
were identiﬁed by Quellung reaction as belonging to sero-
group 6 (6A, 202; 6B, 477); 135 were non-viable or unavail-
able, leaving 544 (80%) invasive isolates belonging to
serogroup 6, of which 168 (83%) had been identiﬁed as 6A
and 376 (79%) as 6B by Quellung reaction. All 168 available
serogroup 6 isolates from non-sterile (mainly upper respira-
tory) sites (63 serotype 6A and 105 serotype 6B) were also
studied, giving a total of 712 presumed serogroup 6 isolates
(231 6A and 481 6B).
PCR ampliﬁcation
All isolates were tested by serogroup 6 serotype-speciﬁc
PCRs, which were performed as previously described
[10,12]. Forty randomly selected serotype 6A, 27 randomly
selected serotype 6B and all serotype 6C and 6D isolates
were subjected to multilocus sequence typing (MLST) by a
standard method [13] with modiﬁcations [14]. Three cps
gene regions (wzg-wzh(cpsA-cpsB), wchA-wciNbeta-wciO and
wciP) were ampliﬁed as previously described [12,15].
Sequencing and sequence analysis
The PCR products of seven alleles in MLST and three cps
gene regions were puriﬁed and sequenced as described pre-
viously [12,15]. The MLST sequences were compared at
https://www.mlst.net/. Sequences for three regions of cps
genes were compared with GenBank sequences of serotype
6C and 6D cps loci (accession numbers EF538714 and
EU714777, respectively) and our previously submitted
sequences [10]. All sequences were analysed with the
BLASTn tool in BIOMANAGER (http://biomanager.info/).
Antimicrobial susceptibility tests
Susceptibilities to chloramphenicol, erythromycin and tetra-
cycline, of all serotype 6C and 6D isolates, were tested by
the Kirby–Bauer technique and MICs of penicillin and
ceftriaxone were determined by E-test (AB Biodisk, Solna,
Sweden). All susceptibility tests were performed and inter-
preted according to CLSI recommendations and deﬁnitions
[16]. To allow comparison with previous studies, penicillin
MICs were interpreted according to the new oral penicillin
breakpoints, established in 2008 (susceptible, £0.06 lg/mL;
intermediate, 0.12–1 lg/mL; and resistant, ‡2 lg/mL).
GenBank submission
Fourteen new 6C and 6D nucleotide sequences were sub-
mitted to GenBank (Table 3).
Results
Serotype-speciﬁc PCR identiﬁcation, distribution and
sources of serogroup 6 isolates in NSW
Ten of 712 presumed serogroup 6 isolates were not ampli-
ﬁed by the 6A/6B PCR; repeat Quellung testing conﬁrmed
that they did not belong to serogroup 6, so they were
excluded. Serotype-speciﬁc PCR for the remaining 702 iso-
lates showed that 197 belonged to serotype 6A (28.1%;
140 invasive, 57 from non-sterile sites); 452 to 6B (64.4%;
355 invasive); 52 to 6C (7.4%; 42 invasive) and one to 6D
(isolated in 2008 from a blood culture of a 68-year-old
man). Discrepant PCR and Quellung results for 26 isolates
were resolved by retesting, which conﬁrmed the PCR
results; 22 isolates previously identiﬁed as 6B were reas-
signed to 6A and four previously identiﬁed as 6A were
reassigned to 6B.
We divided 536 invasive serogroup 6 isolates into two
groups according to the ages of patients from whom they
were isolated: £5 years (the main high-risk group targeted by
infant vaccine) and >5 years. In addition, we divided the total
time period (excluding 1999, when referral of isolates was
incomplete) into two time periods—prevaccine: 2000–2005
and postvaccine: 2006–2008. The annual average numbers of
serogroup 6 isolates referred fell from 62.1 in 2000–2005 to
49.7 in 2006–2008, following the introduction of PCV7 in
2005. In both age groups, serotype 6B was dominant among
serogroup 6 isolates in the ﬁrst period, but the proportion
fell signiﬁcantly, especially in the younger age group, in 2006–
2008 (Table 1). In both age groups the differences in propor-
tions of 6B isolates between prevaccine and postvaccine
periods (2000–2005 vs 2006–2008) were highly signiﬁcant
(age group £5 years: v2 = 15.36, df = 2, p 0.0005; age group
‡5 years: v2 = 50.43, df = 2, p <0.0005).
The proportions of serotype 6A among serogroup 6 iso-
lates did not change signiﬁcantly overall or in either age
group between periods. However, the average annual num-
bers of 6A isolates referred fell between the prevaccine
(2000–2005) and postvaccine (2006–2008) periods from 5.2
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to 2 in the vaccine target group whereas it rose from 10 to
13 in the >5-year age group. The absolute numbers and pro-
portions of serotype 6C increased, overall and in both age
groups, between time periods (Table 1). This difference was
statistically signiﬁcant in the ‡5 year age group (v2 = 19.98,
df = 2, p <0.0005) but numbers of isolates in the <5 year
age group were too small to demonstrate statistical signiﬁ-
cance.
Antibiotic susceptibility of invasive and non-invasive sero-
type 6C and 6D isolates
Two of the 52 (4%) serotype 6C isolates showed intermedi-
ate susceptibility to penicillin and one (2%) was resistant to
erythromycin. The remaining 6C isolates and the one 6D
isolate were susceptible to all ﬁve antibiotics tested.
MLST distribution among serotype 6A, 6B, 6C and 6D
isolates in NSW
The distribution of MLSTs, for 120 serogroup 6 isolates, is
shown in Table 2. There were 12 sequence types (STs),
including ﬁve new ones (ST4237–4240 and ST4242) among
52 serotype 6C isolates; 18 STs, including seven new ones
(ST4237, 4269–4274) among 40 serotype 6A isolates; 15
STs, including ten new ones (ST3999, ST4275–4283)
among 27 serotype 6B isolates; the serotype 6D isolate
belonged to new ST4241. All new ST sequences were sub-
mitted at http://www.mlst.net/. Based on a minimum simi-
larity of ﬁve identical loci, eBURST analysis (Fig. 1) showed
two clonal complexes (CCs, in which a predicted founder
was identiﬁed), seven groups (in which there was no pre-
dicted founder) and 18 singletons with different STs
(Table 2; Fig. 1).
Diversity of capsular genes for serotype 6C isolates in NSW
Sequence types based on variation in three different cps gene
cluster regions are shown in Table 3. Among serotype 6C
isolates, there were ten wchA-wciNbeta-wciO STs, one of which
(type 10) we had identiﬁed previously among 6C isolates
from Fiji [10]. Nine STs were distinguished by only one or
two single nucleotide polymorphisms (SNPs) but type 10 dif-
fered by four base mutations. There were four cpsA-cpsB
STs, including two new ones (types 2 and 3), which varied
by multiple SNPs, and three wciP STs, including one new type
(type 3), which differed by one or two SNPs. wciP type 1
(FJ899601) had been found previously among serotype 6C
isolates from Fiji [10].
Comparison of MLST and three cps sequence types of sero-
type 6C isolates
In our previous study, we demonstrated sequence polymor-
phisms in the cpsA-cpsB region, among serogroup 6 isolates
[15] and in the wchA-wciN-wciO region between serotypes 6C
and 6D among isolates from Fiji [10]. For this reason, we
used these regions to identify cps proﬁles (concatenated in
the order cpsA-cpsB, wchA-wciN-wciO, wciP). Our cps proﬁles
differ from those described by Mavroidi et al., which refer to
genes wciP-wzx-wzy [17]. Comparison of MLST and three cps
STs among serotype 6C isolates is shown in Table 4. In all,
the 52 serotype 6C isolates were divided into 17 cps pro-
ﬁles, based on all three cps gene regions, and 12 MLSTs.
Generally, there was a fair correlation between cps proﬁles
and MLST. However, 16 isolates belonging to ST1715 were
divided among four cps STs and ten isolates belonging to a
single cps proﬁle (1-2-2) were divided among ﬁve STs
(ST600, ST1379, ST1390, ST4238 and ST4242).
TABLE 1. Distribution of invasive serogroup 6 (SG-6) in New South Wales, Australia, by year and in different age groups
Year
Numbers of referred invasive isolates
All ages Age £5 yearsa Age >5 yearsa
Total
isolatesb
SG-6c
(% of total)
Serotypes (% of SG-6)
Total
SG-6
Serotypes (% of total SG-6)
Total
SG-6
Serotypes (% of total SG-6)
6A 6B 6C 6A 6B 6C 6A 6B 6C
1999 95 14 (15) 2 (14) 12 (86) 0 7 1 6 0 7 1 6 0
2000 631 61 (10) 9 (15) 46 (75) 6 (10) 2000–2005
2001 668 67 (10) 13 (19) 54 (81) 0 152 31 (20) 119 (78) 2 (1) 221 60 (27) 151 (68) 10 (5)
2002 781 61 (8) 15 (25) 46 (75) 0
2003 729 50 (7) 9 (18) 40 (80) 1(2)
2004 873 77 (9) 22 (29) 53 (69) 2 (3)
2005 613 57 (9) 23 (40) 31 (54) 3 (5)
2006 702 65 (9) 13 (20) 45 (69) 7 (10) 2006–2008
2007 489 46 (9) 17 (37) 18 (39) 11(24) 19 6 (32) 7 (37) 6 (32) 130d 39 (30) 65(50) 25 (20)
2008 516 38d (7) 15 (39) 9 (24) 13 (34)
Total 6097 536d (9) 138 (26) 354 (66) 43 (8) 178 38 (21) 132 (74) 8 (4) 358d 100 (28) 222 (62) 35 (10)
aBecause of small numbers in each age group, years were grouped into 2-year periods (excluding 1999, when referral was incomplete).
bAll Streptococcus pneumoniae invasive isolates referred for serotyping during the period 1999–2008.
cInvasive serogroup 6 isolates which were available for testing and conﬁrmed as serotypes 6A, 6B, 6C or 6D (one isolate only) by PCR.
dAmong 38 invasive serogroup 6 isolates collected in 2008 (130 in ‡5-year age group, 2006–2008), one from an adult was identiﬁed as serotype 6D.
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Discussion
In countries where PCV7 has been used extensively in
infants, there have been highly signiﬁcant falls in the rates of
invasive pneumococcal disease caused by vaccine (and some
related) serotypes, particularly in the vaccine target age
group but also, because of herd immunity, in older age
groups [18–22]. However, serotype replacement under the
pressure of vaccine use has been reported [23–25]. Strepto-
coccus pneumoniae serotype 6C was ﬁrst described in 2007,
but was identiﬁed among stored isolates from as early as
1979 [3]. Subsequently, several studies have shown that it
was generally uncommon (representing 2–3% of S. pneumo-
niae isolates) among both colonizing and invasive isolates
before the introduction of PCV7 [7,26] but has since
increased in several countries [5–7,27,28]. For example, the
Centers for Disease Control and Prevention Active Bacterial
Core surveillance showed an increase in the proportion of
serotype 6C isolates among those initially identiﬁed as 6A by
Quellung reaction, from 16.4% in 1999 to 69.1% in 2006 [5]
and an increase in the rate of invasive disease caused by
serotype 6C from 0.22 to 0.58 per 100 000 population,
whereas those caused by serotypes 6A and 6B decreased
TABLE 2. Distribution of multilocus sequence types among 120 serotype 6A, 6B, 6C and 6D isolates in New South Wales,
Australia
Clonal complexes/
groups (n)a
MLST allelic proﬁle for 6A, 6B, 6C and 6D
Sequence
typesd
No. of isolates for serotype (n)
Serotype shared
by sequence typeiaroE gdh gki Recp spi xpt ddl 6A (40) 6B (27) 6C (52) 6D (1)
gr1 (9) 7 13 9 6 10 6 14 4241e 1 6D
7 13 8 10 10 6 14 4282f 1 6B
11 13 8 6 10 6 14 4283f 1 6B
7 13 8 6 10 246 14 4278f 2 6B
7 97 27 6 10 6 14 1645 2 6B
7 97 27 6 10 246 14 4277f 2 6B
gr2 (17) 2 40 4 19 10 1 27 2068 1 6A/10Aj
2 7 4 10 10 1 27 65 7 6A
5 7 4 10 10 1 27 460 9 6A
CC1692 (7) 1 5 74 12 17 158 14 4239g 5 6C
1 5 7 12 17 158 14 1692 1 6A
1 5 7 12 17 1 14 395 1 6A
CC1092 (21) 2 13 2 1 9 19 14 4237h,g 1 14 6A/6C
2 13 2 1 6 19 14 1092 1 2 6A/6B/6C/19Al
2 13 9 1 6 19 14 490 3 6A
gr7 (6) 5 6 1 2 6 3 4 90 5 6B
5 6 9 2 6 3 4 3999f 1 6B
gr6 (4) 7 25 4 4 15 20 28 473 3 6A/6B/6C
8 25 4 4 15 20 28 4270h 1 6A
gr8 (5) 1 5 9 12 94 28 20 1379 4 6A/6C
1 5 9 12 6 28 20 4238g 1 6C
gr5 (6) 33 1 40 13 6 1 5 4273h 5 6A
10 1 40 13 6 1 5 4272h 1 6A
gr9 (3) 32 28 1 1 15 19 14 4280f 2 6B
32 28 1 2 15 19 14 4281f 1 6B
Singleton STs (42) 1 25 72 1 15 20 28 690 1 6A
8 8 19 16 6 1 14 4271h 1 6A
2 8 4 131b 6 1 11 4274h 1 6A
7 5 4 5 6 1 18 4269h 1 6A
4 4 2 4 4 1 15 3604 1 6A/23Fk
7 6 1 1 6 15 14 145 3 6B
7 22 1 2 5 1 14 185 3 6B
7 6 4 2 10 15 14 1518 1 6B
6 28 1 2 6 1 5 4275f 1 6B
7 62 1 2 6 1 31 4276f 1 6B
7 5 8 5 10 246 6 4279f 1 6B
1 5 9 43 94 1 346c 4242g 2 6C
93 25 4 15 17 20 8 4240g 1 6C
10 13 1 43 98 1 20 1390 1 6A/6C
2 10 54 4 6 3 14 1669 1 6A/6C
13 1 1 5 6 1 18 1715 1 16 6A/6C
7 25 8 6 25 6 8 1150 2 6B/6C
5 10 9 43 13 1 14 600 3 6A/6C
MLST, multilocus sequence types; ST, sequence types.
aClustering by eBURST analysis of 120 isolates in this study showed two clonal complexes or seven groups and 18 singleton STs (represented by 1–16 isolates) based on a
minimum similarity of ﬁve identical loci.
b,cNew allele of recp 131 and new allele of ddl 346.
dSequence types of 120 isolates in this study.
e–hRepresent MLST not previously described among serotypes 6A, 6B, 6C and 6D.
iSequence type/serotype combinations previously described in published literature and http://www.mlst.net.
j–lST2608 previously described in serotypes 6A and 10A, ST3604 in serotype 6A and 23F. ST1092 in serotype 6A, 6B, 6C and 19A.
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signiﬁcantly [5]. In Massachusetts the proportion of serotype
6A among nasopharyngeal pneumococcal isolates fell from
9.6% before 2001 to 2.9% in 2007 and that of serotype 6C
increased from 0.6% to 8.7% [6].
In common with other reports, we have demonstrated a
dramatic fall in number and proportion of serotype 6B
among invasive pneumococcal isolates and increases in the
numbers and proportions of serotype 6C since the introduc-
tion of PCV7 in NSW. Serotype 6C increased from 11.4%
(12/105) of invasive isolates, originally serotyped as 6A by
Quellung reaction, in the period 1999–2005 (before routine
use of PCV7), to 40.8% (31/76), in the period 2006–2008.
The explanation for the emergence of serotype 6C appar-
ently lies in the observation that PCV7 elicits little opsono-
phagocytic activity against serotype 6C, compared with 6A
and 6B strains [6,29]. Contrary to the ﬁndings of others, we
did not demonstrate any signiﬁcant change in numbers or
proportions of invasive serotype 6A isolates, overall, after
the introduction of PCV7. However, there were differences
between age groups in that the average annual numbers of
referred 6A isolates from older children and adults rose,
whereas the proportion of 6A isolates from children under
ﬁve fell, reﬂecting the effect of immunization. The possibility
that the relatively modest changes in 6A prevalence could
reﬂect a lower level of protection from the three-dose infant
immunization schedule, as used in Australia, compared with
the four-dose schedules used elsewhere, deserves consider-
ation. On the other hand, previous studies have questioned
the need for a fourth (booster) dose [30].
Several studies have reported relatively high levels of mul-
tidrug resistance among serotype 6C isolates [7,26] and, in
one, the rates increased signiﬁcantly between 1999 and 2007
[7]. Again, contrary to these ﬁndings, most of our 6C iso-
lates were fully susceptible to penicillin and erythromycin
and none was multidrug resistant. Nahm et al. also found
that 6C isolates were more susceptible to penicillin than 6A
isolates [6]. Presumably, these differences reﬂect local antibi-
otic use and indicate that the emergence of serotype 6C is
primarily the result of immune pressure from vaccine use,
rather than antibiotic pressure.
In common with other studies, we found considerable
genotypic diversity among serogroup 6, including serotype
6C, isolates (Table 2). Several 6C-related STs were shared
with 6A, including two (ST1715 and ST4237) that accounted
for 58% of the serotype 6C isolates in the study. This ﬁnding
supports the conclusion that serotype 6C is frequently
derived from 6A as a result of recombination [3,5]. None of
our 6C isolates shared STs with the 6B isolates tested in this
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FIG. 1. Genetic relatedness of 120 serogroup 6 Streptococcus pneumoniae isolates in New South Wales, Australia. Clonal complexes (CCs),
groups and singletons were determined by eBURST analysis using all allelic proﬁles reported in the multilocus sequence typing (MLST) database.
The 42 sequence types (STs; black dots) detected in this study are represented. The sizes of the dots correspond to the number of isolates
sharing the same ST. Within CCs (elliptic shapes) missing links (STs present in the MLST database but not found in the present study) are not
represented. CC names refer to the predicted founder if any (i.e. CC1092 refers to ST1092 as predicted founder); ‘gr’ refers to the eBURST
group if no founder is predicted.
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study, but ST1092 (shared by 6A and 6C in our study) has
been previously associated with both 6B and 6C [27]. Our
single 6D isolate belonged to a previously unknown ST4241,
which is a single locus variant of ST176, commonly associ-
ated with serotype 6B [27]. This ﬁnding is compatible with
the assumption that wciNbeta has been directly introduced
into 6B. The wchA-wciNbeta-wciO region sequence for this iso-
late differs by one SNP, compared with the reference
sequence.
The combination of MLST and cps proﬁles demonstrated a
high genetic diversity of serotype 6C isolates. We identiﬁed
only two CCs among 6C isolates (CC1092 and gr8) in this
study; all other STs were singletons. CC1092 included 14
isolates belonging to ST4237 and two belonging to ST1092,
which differed by 14 bases between spi 6 and spi 9 alleles,
suggesting recombination. The 14 ST4237 isolates had three
cps proﬁles that differed from each other by only one SNP
in the wchA-wciNbeta-wciO region. Group 8 includes four
ST1379 isolates and one ST4238 isolate. The differences
between these STs include one SNP between spi alleles.
Most singleton STs, except those with only one isolate,
showed variation (Table 4). For example, 16 isolates belong-
ing to ST1715 produced four cps proﬁles that differed from
each other by one or two SNPs in the wchA-wciNbeta-wciO
region. These SNPs could be the result of either recombina-
tion or point mutation, but it has been shown that, in Escher-
ichia coli, an SNP in a housekeeping gene is 10 to 50 times
more likely to result from recombination than mutation [31].
In conclusion, all four pneumococcal serogroup 6 sero-
types (6A, 6B, 6C and 6D) were represented among isolates
referred to the NSW Pneumococcal Reference Laboratory
between 1999 and 2008. The changes in numbers and pro-
portions of different serotypes, including a signiﬁcant
increase in 6C and fall in 6B between two time periods
TABLE 3. Components of the three cps gene proﬁles for
serotype 6C and 6D isolatesa
Sequence
typesb
No. of
isolates
GenBank
accession no.c
Nucleotide
differences
cpsA-cpsB-6C-1 35 1- EF538714 Reference sequenced
cpsA-cpsB-6C-2 15 2- GQ871848b Multiple
cpsA-cpsB-6C-3 1 3- GQ871849b Multiple
cpsA-cpsB-6C-4 1 4- AF246897 Multiple
cpsA-cpsB-6D 1 5- GQ871850b Single
wchA-wciNbeta-wciO-6C-1 23 1- GQ871838
b Reference sequencec
wchA-wciNbeta-wciO-6C-2 11 2- GQ871839
b Single
wchA-wciNbeta-wciO-6C-3 7 3- GQ871840
b Single
wchA-wciNbeta-wciO-6C-4 4 4- GQ871841
b Single
wchA-wciNbeta-wciO-6C-5 2 5- GQ871842
b Two nucleotides
wchA-wciNbeta-wciO-6C-6 1 6- GQ871843
b Two nucleotides
wchA-wciNbeta-wciO-6C-7 1 7- GQ871844
b Single
wchA-wciNbeta-wciO-6C-8 1 8- GQ871845
b Single
wchA-wciNbeta-wciO-6C-9 1 9- GQ871846
b Single
wchA-wciNbeta-wciO-6C-10 1 10- FJ899597 Four nucleotides
wchA-wciNbeta-wciO-6D 1 2- GQ871847
b Single
wciP-6C-1 33 1- FJ899601 Reference sequencec
wciP-6C-2 12 2- EF538714 Two nucleotides
wciP-6C-3 7 3- GQ871851b Single
wciP-6D - 1 4- EU714777 Multiple
acps gene proﬁles consist of alleles of each of three genes/regions in the order
shown: cpsA-cpsB-6C 1–4; wchA-wciNbeta-wciO-6C 1–10; wciP-6C 1–3 (and corre-
sponding sequence for 6D, for which only a single isolates/genotype has so far
been characterized (see Table 4).
bSequence type nomenclature is based on the predominance of individual
sequence types (1, 2, 3, etc. in decreasing order of prevalence).
cNew sequences have been submitted to GenBank.
dThe commonest allele for each cps gene sequence is characterized as the refer-
ence sequence.
TABLE 4. Comparison of multilocus sequence types and cps gene proﬁles of serotype 6C isolates
MLST
(No. of isolates)
cps gene sequence
type proﬁlesa
(No. of isolates)
cps gene targeta
allele number- GenBank accession no.
cpsA-cpsB
(4 alleles)
wchA-wciNbeta-wciO
(10 alleles) wciP (3 alleles)
600 (3); 1379 (4); 1390 (1);
4238 (1); 4242 (1)
1-2-2 (10) 1- EF538714 2- GQ871839 2- EF538714
4242 (1) 1-1-2 (1) 1- EF538714 1- GQ871838 2- EF538714
1092 (2) 2-1-1 (1) 2- Q871848 1- GQ871838 1- FJ899601
4-1-1 (1) 4- AF246897 1- GQ871838 1- FJ899601
1150 (2) 1-5-2 (1) 1- EF538714 5- GQ871842 2- EF538714
1-5-3 (1) 1- EF538714 5- GQ871842 3- GQ871851
1669 (1) 1-2-3 (1) 1- EF538714 2- GQ871839 3- GQ871851
1715 (16) 1-1-1 (5) 1- EF538714 1- GQ871838 1- FJ899601
1-3-1 (6) 1- EF538714 3- GQ871840 1- FJ899601
1-4-1 (4) 1- EF538714 4- GQ871841 1- FJ899601
1-6-1 (1) 1- EF538714 6- GQ871843 1- FJ899601
4237 (14) 2-1-1 (12) 2- GQ871848 1- GQ871838 1- FJ899601
2-3-1 (1) 2- GQ871848 3- GQ871840 1- FJ899601
2-7-1 (1) 2- GQ871848 7- GQ871844 1- FJ899601
4239 (5) 1-1-3 (3) 1- EF538714 1- GQ871838 3- GQ871851
3-8-3 (1) 3- GQ871849 8- GQ871845 3- GQ871851
1-9-3 (1) 1- EF538714 9- GQ871846 3- GQ871851
4240 (1) 1-10-1 (1) 1- EF538714 10- GQ871847 1- FJ899601
MLST, multilocus sequence types.
acps gene proﬁle (or sequence type) is represented by combinations of different alleles at each of three cps gene regions sequenced; proﬁles are represented by a three-digit
code in the order shown in Table 3. The corresponding GenBank accession number for each allele is shown.
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(2000–2005 and 2006–2008), were apparently related to the
widespread use of PCV7. Both mutation and recombination
may have contributed to genotypic diversity among serotype
6C isolates and its rapid increase in prevalence suggests that
it has the potential to replace 6B as the predominant invasive
serogroup 6 serotype. Proﬁling of the cps gene is a useful
genotyping method, which will potentially complement MLST
in studies of epidemiology and population diversity of sero-
type 6C.
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